Explore

Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders
Trendline Trendline
Coeur Mining Expands with New Gold Acquisition, Boosts Shareholder Returns

Coeur Mining Expands with New Gold Acquisition, Boosts Shareholder Returns

Coeur Mining Expands with New Gold Acquisition, Boosts Shareholder Returns
Trendline Trendline
Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements
Trendline Trendline
Kessler Topaz Meltzer Check, LLP Urges Soleno Therapeutics Investors to Join Class Action Lawsuit

Kessler Topaz Meltzer Check, LLP Urges Soleno Therapeutics Investors to Join Class Action Lawsuit

Kessler Topaz Meltzer Check, LLP Urges Soleno Therapeutics Investors to Join Class Action Lawsuit
Trendline Trendline
Faruqi Faruqi, LLP Alerts Ultragenyx Pharmaceutical Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Ultragenyx Pharmaceutical Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Ultragenyx Pharmaceutical Investors of Securities Class Action Deadline
Trendline Trendline
Kessler Topaz Meltzer Check, LLP Files Securities Fraud Lawsuit Against Soleno Therapeutics

Kessler Topaz Meltzer Check, LLP Files Securities Fraud Lawsuit Against Soleno Therapeutics

Kessler Topaz Meltzer Check, LLP Files Securities Fraud Lawsuit Against Soleno Therapeutics
Trendline Trendline
Eshbal Functional Food Inc. Reports Record Q1 2026 Revenues Driven by Acquisitions

Eshbal Functional Food Inc. Reports Record Q1 2026 Revenues Driven by Acquisitions

Eshbal Functional Food Inc. Reports Record Q1 2026 Revenues Driven by Acquisitions
Trendline Trendline
Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline
Trendline Trendline
Pharma M Activity Surges with Record Highs Anticipated in 2026

Pharma M Activity Surges with Record Highs Anticipated in 2026

Pharma M Activity Surges with Record Highs Anticipated in 2026
Trendline Trendline
SV Health Investors Acquires EpiVax, Expanding Pharma Services Portfolio

SV Health Investors Acquires EpiVax, Expanding Pharma Services Portfolio

SV Health Investors Acquires EpiVax, Expanding Pharma Services Portfolio
Trendline Trendline
Coeur Mining's Price Target Lowered Amid Weaker Gold and Silver Outlook

Coeur Mining's Price Target Lowered Amid Weaker Gold and Silver Outlook

Coeur Mining's Price Target Lowered Amid Weaker Gold and Silver Outlook
Trendline Trendline
Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans

Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans

Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans